(Q39557396)

13 September 2017

title

MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes (English)

1 reference

13 September 2017

1 reference

1 reference

S Fujii

1

1 reference

13 September 2017

K Tokita

2

1 reference

13 September 2017

N Wada

3

1 reference

13 September 2017

K Ito

4

1 reference

13 September 2017

C Yamauchi

5

1 reference

13 September 2017

Y Ito

6

1 reference

13 September 2017

A Ochiai

7

1 reference

13 September 2017

language of work or name

English

0 references

publication date

18 April 2011

1 reference

13 September 2017

1 reference

13 September 2017

volume

30

1 reference

13 September 2017

issue

39

1 reference

13 September 2017

page(s)

4118-4128

1 reference

Rac is activated by erythropoietin or interleukin-3 and is involved in activation of the Erk signaling pathway

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Role of histone H3 lysine 27 methylation in Polycomb-group silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Triple-negative breast cancer: therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

BRCA1 mutations in primary breast and ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Basal carcinoma of the breast revisited: an old entity with new interpretations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Evidence that phosphorylation of the RNA polymerase II carboxyl-terminal repeats is similar in yeast and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Role of histone H3 lysine 27 methylation in X inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Genome regulation by polycomb and trithorax proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

RUNX3, a novel tumor suppressor, is frequently inactivated in gastric cancer by protein mislocalization.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.118

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.118

1 reference

13 September 2017

1 reference